ArticleBioinformatics (Oxford, England)2026
Bayesian hyperparameter optimization improves scGPT fine-tuning for single-cell multi-omics integration.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
motivationFoundation models such as scGPT have demonstrated strong potential for single-cell multi-omics integration; however, their downstream performance is highly sensitive to hyperparameter selection. Manual fine-tuning remains computationally expensive, dataset-dependent, and often irreproducible. Despite the increasing adoption of foundation models in single-cell analysis, systematic strategies for robust hyperparameter optimization remain underexplored.
resultsWe developed a Bayesian optimization framework based on Tree-structured Parzen Estimators (TPE) for automated fine-tuning of scGPT and evaluated its performance on two benchmark bone marrow mononuclear cell (BMMC) multi-omics datasets, including CITE-seq and GSE194122 datasets. Across datasets, Bayesian optimization consistently improved biological conservation and batch integration metrics compared with default scGPT configurations. On the original BMMC benchmark, optimization improved AvgBIO from 0.59 to 0.67 and PCR from 0.33 to 0.52. On the GSE194122 dataset, the default configuration exhibited unstable convergence and weak biological preservation (AvgBIO = 0.19; ARI = 0.007), whereas Bayesian optimization substantially improved integration performance (AvgBIO = 0.60; ARI = 0.63) while reducing validation loss from 137 to 47.1. These findings demonstrate substantial dataset-specific sensitivity of scGPT fine-tuning and highlight the importance of automated optimization for stable deployment across heterogeneous multi-omics datasets. Our study demonstrates that Bayesian optimization provides an effective and reproducible strategy for stabilizing scGPT fine-tuning across diverse single-cell multi-omics datasets. Rather than introducing a new integration architecture, this work emphasizes the importance of systematic optimization for improving robustness and reproducibility of foundation-model applications in computational biology. AVAILABILITY AND IMPLEMENTATION: Our model and dataset are freely available at: https://github.com/daren642/scGPT_multiomic_tuning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.